via www.examiner.com
New medication also reduces by 40 percent the number of pulmonary exacerbations, the leading cause of death in cystic fibrosis patients
Results from two phase 3 clinical trials published today in the New England Journal of Medicine show that a new combination of medications can successfully treat the underlying cause of cystic fibrosis for patients age 12 and older with two copies of the F508del gene mutation – the most common form of the life-threatening, genetic disease found in over half of the cystic fibrosis (CF) population. Approximately 8,500 people in the U.S., and 22,000 people in North America, Europe and Australia, age 12 and older with cystic fibrosis carry this gene mutation.
The international trial, which studied more than 1,000 cystic fibrosis patients age 12 and older, revealed that a combination of the drugs Kalydeco (ivacaftor) and lumacaftor, an experimental drug that has not yet been approved by the Food and Drug Administration (FDA), successfully treated the defective CF protein and improved lung function. The drugs also helped patients achieve a 40 percent reduction in pulmonary exacerbations, the leading cause of death in cystic fibrosis patients.
“Being able to treat not just the symptoms, but the underlying cause of cystic fibrosis by targeting this specific gene mutation, is a major game changer because it is by far the most common in patients with this disease,” said Dr. Bonnie Ramsey, director of the Center for Clinical and Translational Research at Seattle Children’s Research Institute and professor of Pediatrics at the University of Washington, who presented the study’s findings at the Center for Drug Evaluation and Research advisory committee meeting on May 12. “Previously, we found that Kalydeco treated just four percent of cystic fibrosis patients, but this new combination treats the defective CF protein for a much greater number of patients.”
The drugs, which work together to address the defective gene mutation by allowing the proteins within the cell to fold properly, reach the cell surface and then work as a salt channel, were given to patients over the course of 24 weeks in an effort to gain insight on how they may improve lung function and quality of life for people living with cystic fibrosis.
The trial included cystic fibrosis patients from Seattle Children’s and the University of Washington Medical Center. Today, the median predicted age of death for a person with the disease is in the mid-20s.
“What gives me tremendous confidence and excites me the most are the comprehensive health improvements seen in patients across all age groups, in all geographies and with all levels of disease severity,” said Ramsey, who was one of four lead authors on the trial and is a pioneer in cystic fibrosis treatment. “Patients can now have longer periods of good health, greatly improving their quality of life.”
The Latest on: Cystic Fibrosis
[google_news title=”” keyword=”Cystic Fibrosis” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cystic Fibrosis
- A cure for cystic fibrosis? Pharma companies must lower their prices firston December 6, 2023 at 11:00 pm
The hesitation of the National Institute for Health and Care Excellence (NICE) in sanctioning a “miracle” drug for Cystic Fibrosis, as recently reported in this paper, might seem harsh and unfair.
- West Wicklow pub has Christmas fundraiser for cystic fibrosison December 6, 2023 at 7:00 pm
The West Wicklow House pub in Blessington hosted a Christmas market with all the trimmings to raise funds for Cystic Fibrosis Ireland.
- 'Miracle' mum Tina Lee becomes first Australian cystic fibrosis patient to receive rheumatoid arthritis drug in experimental treatmenton December 5, 2023 at 3:46 pm
Tina thought she would never see her baby son again after her health deteriorated eight years after a double lung transplant. But behind the scenes, her medical team were thinking "outside the box".
- The Guardian view on cystic fibrosis treatments: a rollercoaster ride for the sickon December 5, 2023 at 11:32 am
Editorial: Patients are facing shorter lives as drug companies are demanding prices that health services here and in other countries cannot pay ...
- Cystic fibrosis sufferer overcomes pregnancy complicationon December 5, 2023 at 5:11 am
Doctors have succeeded in their desperate attempt to save the life of a new mum who thought she'd never see her newborn son again.
- Fears son's age may deny cystic fibrosis drugon December 5, 2023 at 12:43 am
A baby with cystic fibrosis may be denied a life-changing drug because of his age, his mum has said. Archie, who is 13 months old, from Ponteland, Northumberland, was diagnosed with the genetic ...
- Tina Lee has cystic fibrosis and thought she was dying when her newborn baby Henry was just five days old.on December 4, 2023 at 11:24 am
Trusted and independent source of local, national and world news. In-depth analysis, business, sport, weather and more.
- Families in NHS funding plea for life-changing cystic fibrosis drugon December 3, 2023 at 10:18 pm
Kaftrio is a drug which can enhance the life expectancy of someone with cystic fibrosis by around forty years. But now its availability on the NHS is under threat. Zara's mother, Fiona, said: "Zara is ...
- Cystic Fibrosis (CF) Therapeutics Global Research Report 2023: Market to Reach $10.11 Billion in 2027 - Long-term Forecast to 2032on November 29, 2023 at 7:33 am
Therapeutics Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global cystic fibrosis (CF) therapeutics market is expected to grow from $5.82 billion in 2022 to ...
- What to Know About Cystic Fibrosis and COVID-19on November 28, 2023 at 4:00 pm
Cystic fibrosis (CF) is a genetic disorder affecting approximately 35,000 people in the United States. It causes sticky mucus to build up in the lungs and digestive system. As CF affects the lungs, ...
via Bing News
